NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

NCT04989816

CompletedPhase 2

Sponsor: AstraZeneca

Conditions: Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Trastuzumab Deruxtecan

Countries: China

This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Male or female ≥ 18 years of age
2. Pathologically documented gastric or GEJ adenocarcinoma
3. Disease progression on or after ≥ 2 prior platinum and fluoropyrimidine agents for advanced/metastatic disease
4. ECOG PS 0-1
5. Willing and able to provide an adequate newly-acquired tumour sample for confirmation of HER2 status
6. LVEF ≥ 50%

Exclusion Criteria:

1. Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and CART. Drainage and CART.
2. Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids
3. Active primary immunodeficiency, known HIV, active HBV, HCV infection.
4. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
5. History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening.
6. Lung-specific intercurrent clinically significant severe illnesses.

Locations (24)

Beijing, China
Beijing, China
Changsha, China
Chengdu, China
Fuzhou, China
Guangzhou, China
Hangzhou, China
Hangzhou, China
Hangzhou, China
Hefei, China
Hefei, China
Jinan, China
Lanzhou, China
Nanchang, China
Nanchong, China
Nanjing, China
Shanghai, China
Shenyang, China
Suzhou, China
Wuhan, China
Xiamen, China
Yinchuan, China
Zhengzhou, China
Zhengzhou, China